A process for producing crystalline ibuprofen having a crystal habit characterized by a particle length larger than 75 microns average and a length to width aspect ratio of greater than about 4 to 1 to about 5 to 1. The process involves crystallizing ibuprofen from a saturated solution of ibuprofen in a liquid hydrocarbon solvent by seeding and cooling such solution to a temperature of about 0.degree. C. to about -20.degree. C. at a rate to retard primary nucleation and promote secondary nucleat...

Provided herein are compositions and methods of making compositions of ibuprofen in combination with a narcotic analgesic. Specifically provided is a pharmaceutical tablet composition comprising ibuprofen; a narcotic analgesic; colloidal silicon dioxide; a filler selected from the group consisting of microcrystalline cellulose and powdered cellulose; a disintegrant selected from the group consisting of croscarmellose sodium, crospovidone, and sodium starch glycolate; a binder consisting of an ak...

The invention relates to the use of a non-steroidal anti-inflammatory drug together with an opioid analgesic in the manufacture of a medicament for the treatment of arthritis.

A process for producing crystalline ibuprofen having a crystal habit characterized by a particle length larger than 75 microns average and a length to width aspect ratio of greater than about 4 to 1 to about 5 to 1. The process involves crystallizing ibuprofen from a saturated solution of ibuprofen in a liquid hydrocarbon solvent by seeding and cooling such solution to a temperature of about 0.degree. C. to about -20.degree. C. at a rate to retard primary nucleation and promote secondary nucleat...

A process for treating Herpes Type II virus by the systemic administration or topical application of ibuprofen (p-isobutylhydratropic acid) or a salt or ester thereof. Dosage forms are also disclosed.

A pharmaceutical preparation containing ibuprofen is disclosed. In the preparation, the ibuprofen particles are enveloped by a coating of a hydro-colloid and fumaric acid. Preferably, the hydro-colloid comprises xanthan gum and/or maltodextrin. This preparation reduces the tendency of ibuprofen to irritate the esophagus and the gastrointestinal tract when taken orally. An effervescent mixture of the ibuprofen containing preparation can be prepared by incorporating citric acid and calcium carbona...

A new process for preparing ibuprofen or its alkyl esters is provided. A 1-halo-1-(4-isobutylphenyl)ethane is reacted with carbon monoxide in the presence of water or an alcohol at a temperature between about 10.degree. C. and about 200.degree. C. An excess of several moles of water or alcohol is preferred. An acid such as hydrochloric acid may also be added. As catalyst, a palladium compound and at least one acid-stable ligand are present; however an excess of ligand over palladium is advantage...

Pharmaceutical compositions for use in the treatment of cough/cold symptoms comprising loratadine, ibuprofen and pseudoephedrine are disclosed.

A process for preparing alkyl esters of ibuprofen is provided. A 1-halo-1-(4-isobutylphenyl)ethane is reacted in an anhydrous medium with carbon monoxide in the presence of an alkoxide source at a temperature between about 10.degree. C. and about 200.degree. C. An excess of several moles of alcohol is preferred. An acid such as hydrogen chloride may also be added. As catalyst, a palladium compound having at least one acid-stable ligand is present; however, an excess of ligand over palladium is a...

A novel neomorphic form of ibuprofen and processes for its preparation are provided. The neomorphic ibuprofen is characterized by having a distinctively less bitter and acidic taste commonly associated with conventional ibuprofen and which causes less burning sensation upon swallowing. The neomorphic form of ibuprofen is an amorphous ibuprofen and is prepared by resolidifying supercooled ibuprofen at a process temperature below 0.degree. C.